ストックスクリーナーアプリを入手
1.41
11.02%
0.14
アフターアワーズ：
1.42
0.01
+0.71%
前日終値:
$1.27
開ける：
$1.26
24時間の取引高:
232.48K
Relative Volume:
0.20
時価総額：
$14.22M
収益：
$960.60K
当期純損益:
$-7.10M
株価収益率:
-0.1865
EPS:
-7.56
ネットキャッシュフロー:
$-8.00M
1週間 パフォーマンス:
+2.92%
1か月 パフォーマンス:
-14.55%
6か月 パフォーマンス:
-25.00%
1年 パフォーマンス:
-58.04%
1日の値動き範囲:
$1.26
$1.43
1週間の範囲:
$1.26
$1.47
52週間の値動き範囲:
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
SNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.41 | 12.81M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-28 | ダウングレード | Dawson James | Buy → Neutral |
| 2018-01-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 繰り返されました | Maxim Group | Buy |
| 2017-07-17 | 開始されました | H.C. Wainwright | Buy |
Soligenix Inc (SNGX) 最新ニュース
What insider purchases suggest about Soligenix Inc. (DOA0) stockPortfolio Value Summary & Accurate Intraday Trade Tips - newser.com
Will Soligenix Inc. (DOA) stock see valuation expansionJuly 2025 Momentum & Accurate Technical Buy Alerts - newser.com
Why Soligenix Inc. stock attracts high net worth investorsTrade Entry Summary & Advanced Swing Trade Entry Plans - newser.com
How Soligenix Inc. stock responds to policy changesMarket Trend Review & Accurate Trade Setup Notifications - newser.com
What insider trading reveals about Soligenix Inc. stockTrade Entry Report & Risk Managed Investment Strategies - newser.com
Will Soligenix Inc. (DOA0) stock gain from lower interest ratesJuly 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Will Soligenix Inc. (DOA) stock keep high P E multiples2025 Pullback Review & Risk Controlled Daily Plans - newser.com
Is Soligenix Inc. stock a buy for dividend growth2025 Market Overview & Trade Opportunity Analysis Reports - newser.com
Is Soligenix Inc. (DOA) stock a buy for dividend portfoliosJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Will Soligenix Inc. (DOA0) stock profit from fiscal stimulus2025 Price Action Summary & Consistent Profit Focused Trading Strategies - newser.com
Can Soligenix Inc. (DOA) stock deliver strong annual returns2025 Market Outlook & Daily Profit Maximizing Trade Tips - newser.com
Is Soligenix Inc. (DOA0) stock safe for risk averse investorsMarket Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Soligenix hits enrollment target for CTCL treatment interim analysis By Investing.com - Investing.com Nigeria
Is Soligenix Inc. (DOA0) stock cheap vs fundamentalsJuly 2025 Intraday Action & AI Enhanced Execution Alerts - newser.com
Soligenix (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte - Digital Journal
Is Soligenix Inc. trending in predictive chart modelsJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Is Soligenix Inc. (DOA0) stock attractive for growth fundsDollar Strength & AI Enhanced Execution Alerts - newser.com
Will Soligenix Inc. (DOA) stock extend growth storyMarket Movement Recap & Free Technical Pattern Based Buy Signals - newser.com
Soligenix Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte for Cutaneous T-Cell Lymphoma – citybuzz - citybuzz
Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte - TipRanks
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - The Malaysian Reserve
Soligenix achieves enrollment milestone for planned interim analysis in confirmatory phase 3 clinical trial of HyBryte for treatment of cutaneous T-cell lymphoma - MarketScreener
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte?? for the Treatment of Cutaneous T-Cell Lymphoma - MarketScreener
Soligenix hits enrollment target for CTCL treatment interim analysis - Investing.com
Soligenix (SNGX) Completes Key Enrollment for Phase 3 Study on C - GuruFocus
Soligenix Inc (SNGX) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):